Highlights

  • Morgan Stanley reiterates Equal Weight rating with $34 price target.
  • EODHD/Others consensus target of $38.62 shows 28.61% valuation gap.
  • Long-term growth estimate stands at 74% on pipeline expectations.

Genmab A/S – ADR (NASDAQ:GMAB) closed at $30.03 on February 13, 2026, gaining $0.44 in the session, as Morgan Stanley maintained its Equal Weight rating and set a $34.00 price target. The brokerage view reflects a more neutral stance compared with several firms that continue to assign Buy ratings, while others have shifted to Hold.

Consensus Estimates and Growth Outlook

Data compiled by EODHD/Others (as of February 16, 2026) indicate a Buy-equivalent overall recommendation, with an average target price of $38.62. This places the consensus valuation 28.61% above the latest closing price of $30.03. The same dataset shows a long-term growth projection of 74%, linked to expectations for the company’s antibody therapeutics pipeline and clinical progress.

Recent Brokerage Actions

Zacks Research downgraded the stock from Strong Buy to Hold, while Wall Street Zen also moved its rating to Hold. Truist Financial reaffirmed its Buy rating and set a $48.00 target price, and HC Wainwright maintained a Buy rating with a $39.00 target. Johnson Rice reiterated its Buy recommendation.

Focus on Antibody Therapeutics Development

Founded in 1999 and headquartered in Copenhagen, Genmab specializes in the discovery and development of antibody-based therapies for cancer. Its research platform is centered on proprietary antibody engineering technologies designed to identify new treatment targets in both hematologic malignancies and solid tumors. The company advances its internally developed molecules from early-stage discovery through clinical development.

On January 21, the company disclosed a marked rise in DARZALEX net sales for 2025. Global revenue from the therapy totaled $14.351 billion, compared with $11.670 billion in 2024. The United States accounted for the majority of sales at approximately $8.266 billion, with international markets contributing the remaining $6.085 billion.